DarioHealth (NASDAQ:DRIO) Issues Quarterly Earnings Results

DarioHealth (NASDAQ:DRIO) posted its quarterly earnings results on Tuesday. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.37, FiscalAI reports. DarioHealth had a negative net margin of 192.23% and a negative return on equity of 60.52%. The company had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $5.92 million.

Here are the key takeaways from DarioHealth’s conference call:

• Revenue declined to $5.2 million from $5.6 million in Q1 and $5.4 million a year ago, reflecting implementation timing and the company’s exit from pharmaceutical-services revenue. Management expects momentum to improve in Q3 and Q4, but most contracted revenue is not expected to contribute until 2027.
• DarioHealth ended Q2 with approximately $13.1 million in contracted and late-stage annual recurring revenue, more than 80% of it multi-condition, and reported over 180 signed employer and health-plan accounts. About 75% of new accounts now come through channel partners, which management says is reducing customer-acquisition costs and sales-cycle times.
• Financial efficiency improved, with gross margin rising to 62%, operating expenses falling 21% year over year, and net loss improving 39% to $7.9 million. Management expects incremental revenue from existing implementations, AI-enabled engagement, and new care offerings to generate meaningful operating leverage.
• The company launched an integrated GLP-1 program and introduced women’s health and sleep programs, expanding its provider-backed care and multi-condition platform. Dario expects DarioIQ to increase recurring revenue from existing customers by approximately 10%–15% over time through improved engagement, retention, and outcomes.
• Pro forma cash increased to $36.8 million following a July registered-direct financing, providing additional runway to execute on commercial opportunities and pursue the company’s path toward cash-flow positivity.

DarioHealth Price Performance

NASDAQ:DRIO traded up $0.07 during trading hours on Tuesday, hitting $7.72. The company’s stock had a trading volume of 37,661 shares, compared to its average volume of 15,221. DarioHealth has a 52-week low of $5.84 and a 52-week high of $17.74. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.62 and a current ratio of 3.07. The business’s 50-day moving average is $7.10 and its two-hundred day moving average is $8.33. The company has a market capitalization of $56.70 million, a PE ratio of -0.87 and a beta of 1.11.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. TD Cowen reiterated a “hold” rating and set a $11.00 target price on shares of DarioHealth in a research note on Wednesday, May 13th. Stifel Nicolaus reiterated a “buy” rating and issued a $10.00 price objective on shares of DarioHealth in a report on Thursday, May 14th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a research report on Friday, July 10th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, DarioHealth has a consensus rating of “Hold” and a consensus target price of $10.50.

Insider Buying and Selling at DarioHealth

In related news, Director Dennis Matheis purchased 14,430 shares of the stock in a transaction dated Thursday, July 23rd. The shares were acquired at an average cost of $6.93 per share, with a total value of $99,999.90. Following the purchase, the director directly owned 43,026 shares in the company, valued at $298,170.18. This trade represents a 50.46% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC purchased a new position in DarioHealth in the fourth quarter valued at about $35,000. Geode Capital Management LLC boosted its position in DarioHealth by 167.9% during the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after purchasing an additional 31,063 shares in the last quarter. Finally, XTX Topco Ltd boosted its position in DarioHealth by 229.0% during the second quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after purchasing an additional 43,513 shares in the last quarter. 33.39% of the stock is currently owned by institutional investors and hedge funds.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.